Journal News

MCP: Researchers closer
to gonorrhea vaccine after
exhaustive analysis of proteins

Steven Lundeberg
By Steven Lundeberg
Jan. 1, 2019

In a study of drug-resistant gonorrhea strains historic in its scope, researchers at Oregon State University have pushed closer to a vaccine for gonorrhea and toward understanding why the bacteria that cause the disease are so good at fending off antimicrobial drugs.

GonorrheaNeisseria gonorrhoeae, the bacterium that causes gonorrhea, is shown here in a scanning electron micrograph.NIAIDThe findings, published in the journal Molecular & Cellular Proteomics, are especially important since the microbe Neisseria gonorrhoeae is considered a “superbug” because of its resistance to all classes of antibiotics available for treating infections.

Gonorrhea, a sexually transmitted disease that results in 78 million new cases worldwide each year, is highly damaging if untreated or improperly treated. It can lead to endometritis, pelvic inflammatory disease, ectopic pregnancy, epididymitis and infertility.

Babies born to infected mothers are at increased risk of blindness. Up to 50 percent of infected women don’t show any symptoms, but those asymptomatic cases still can lead to severe consequences for the patient’s reproductive health, miscarriage or premature delivery.

Aleksandra Sikora, a researcher with the OSU College of Pharmacy and Oregon Health and Science University’s Vaccine and Gene Therapy Institute, helped lead an international collaboration that performed proteomic profiling on 15 gonococcal strains.

Among the isolates in the study were the reference strains maintained by the World Health Organization that show all known profiles of gonococcal antimicrobial resistance.

For each strain, researchers divided the proteins into those found on the cell envelope and those in the cytoplasm. More than 1,600 proteins — 904 from the cell envelopes and 723 from the cytoplasm — were found to be common among all 15 strains, and from those, nine new potential vaccine candidates were identified.

A vaccine works by introducing an “invader” protein known as an antigen that triggers the body’s immune system and subsequently helps it quickly recognize and attack the organism that produced the antigen.

Researchers also found six new proteins that were expressed distinctively in all of the strains, suggesting they’re markers for or play roles in drug resistance and thus might be effective targets for new antimicrobials.

In addition, scientists looked at the connection between bacterial phenotype — the microbes’ observable characteristics and behavior — and the resistance signatures that studying the proteins revealed; they found seven matching phenotype clusters between already-known signatures and the ones uncovered by proteomic analysis.

Together, the findings represent a key step toward new weapons in the fight against a relentless and ever-evolving pathogen.

“We created a reference proteomics databank for researchers looking at gonococcal vaccines and also antimicrobial resistance,” said Sikora, co-corresponding author on the study. “This was the first such large-scale proteomic survey to identify new vaccine candidates and potential resistance signatures. It’s very exciting.”

The findings add new momentum to a vaccine quest that also received a boost in summer 2017, when a study in New Zealand showed that patients receiving the outer membrane vesicle meningococcal B vaccine to prevent Neisseria meningitis were 30 percent less likely to contract gonorrhea than those who didn’t get the vaccine.

“All previous vaccine trials had failed,” Sikora said.

Gonorrhea and meningococcal meningitis have different means of transmission, and they cause different problems in the body, but their source pathogens are close genetic relatives.

This article is republished from the EurekAlert website.

Steven Lundeberg
Steven Lundeberg

Steven Lundeberg is a news writer at Oregon State University.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

St. Jude and maximizing the value of blood
Health Observance

St. Jude and maximizing the value of blood

June 14, 2021

The hospital is most renowned for passing along no costs to families. To facilitate this, the in-house capabilities of St. Jude are second to none. This includes the on-site blood donation facilities.

A balancing game with implications for neurodegenerative disease
Journal News

A balancing game with implications for neurodegenerative disease

June 8, 2021

The relationship between two proteins, one essential to mitochondrial fission and the other found in Alzheimer’s tissue, might hold the key to how disease alters the fission–fusion balance.

Can people vaccinated against COVID-19 still spread the coronavirus?
News

Can people vaccinated against COVID-19 still spread the coronavirus?

June 6, 2021

Preliminary evidence seems to suggest that someone who’s vaccinated is less likely transmit the virus, but the proof is not yet ironclad.

Addgene expands its collection into antibodies
News

Addgene expands its collection into antibodies

June 4, 2021

The reagent repository Addgene, known for distribution and quality control of plasmids for open science, is expanding into recombinant antibodies and nanobodies in partnership with NeuroMab.

Study reveals experimental targets for lymphoma research
Journal News

Study reveals experimental targets for lymphoma research

June 3, 2021

An enzyme previously linked to lymphoma development may have more functions than previously thought.

Exploring underappreciated molecules and new cities
Interview

Exploring underappreciated molecules and new cities

June 2, 2021

Neurochemist Xianlin Han has been an associate editor for the Journal of Lipid Research since 2019.